Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cadila Of India To Reveal Soon New Breakthrough Drug Candidate

This article was originally published in PharmAsia News

Executive Summary

India's Cadila Pharmaceuticals says it plans to introduce soon a drug it expects to lower by one-third the cost of treating tuberculosis. Cadila said it expects to announce the drug Resorine (resorcin) within the next two weeks. Chairman I.A. Modi called the drug a bio-enhancer capable of lowering the dosage of existing TB drugs without sacrificing efficacy. The Cadila drug already has completed Phase III trials and has special protocol approval by U.S. FDA. The Cadila announcement comes just three months after it unveiled its Polycap (atenolol/thiazide) cardiac drug, which it considers a potential blockbuster. (Click here for more

You may also be interested in...

Mylan Bids To Win EU Approval For Upjohn Merger

Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.

IGBA Criticizes Export Restrictions

National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.

Italy’s Dompé Taking Legal Action Over COVID-19 Fake News

Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts